Our latest Survivor Views survey sees increases in biomarker testing since the question was last asked three years ago along with reduced cost and coverage barriers in that time. Cancer patients and survivors describe the benefits and overwhelmingly agree biomarker testing gave their providers information that improved their treatment.
Health Equity in Biomarker Testing and Targeted Therapy
Despite evidence demonstrating the effectiveness of biomarker testing and targeted therapy, currently not all individuals benefit equitably from these advances. There are notable racial/ethnic, and socioeconomic disparities in access and utilization of these advancements in care. These disparities in access and use of guideline-indicated biomarker testing and targeted therapy can potentially widen existing disparities in cancer survival.